Florida Blue is the Largest Healthcare Payer in that State Redwood City, CA, June 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today Blue Cross Blue Shield of Florida (Florida Blue) has
Gynesonics Appoints David Pacitti to Board Chair
Current President and Head of Siemens Healthineers in The Americas Brings Strong Commercial Experience to the Board of Directors Karen Talmadge, Ph.D., Remains as Independent Board Member, Retaining Key Strengths and Experience for Gynesonics Redwood City, CA, June 7, 2021 – Gynesonics®, a
Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for Treatment of Uterine Fibroids with the Sonata System
The national policy covers approximately 15 million lives in 48 states and Washington D.C. for this minimally invasive, uterine-preserving and incision-free treatment Redwood City, CA, June 3, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive
New Guidance from the American College of Obstetricians and Gynecologists for Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation as a Uterus-Preserving Treatment Option
Additionally, an expert physician panel in Europe reached consensus and published a new recommended fibroid treatment algorithm with transcervical radiofrequency ablation (Sonata) at the forefront Redwood City, CA, June 1, 2021 – Gynesonics®, a women’s healthcare company focused on the development
Gynesonics Announces Publication of SAGE Global Registry Preliminary Results: Real-World Usage Corroborates the Safety and Applicability of Sonata Transcervical Fibroid Ablation
The initial results of the first 160 treated women in the Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE) show the broad applicability of Transcervical Fibroid Ablation performed by the Sonata System to a wide range of fibroid types and sizes while maintaining an
Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids
The analysis shows that fibroids, which are often treated by hysteroscopic resection or morcellation, can be effectively treated with the Sonata® System, the only incision-free, transcervical procedure that can treat most submucous, intramural, subserous, transmural and large fibroids REDWOOD CITY,
Gynesonics Appoints Susan Stimson To Its Board of Directors
Executive with Extensive Commercialization Experience to Provide Key Insights on Global Launch Strategies Redwood City, CA, March 18, 2021– Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that
Gynesonics Announces Positive Payer Coverage Issued by Health Care Service Corporation (HCSC) for the Sonata Treatment
HCSC is the largest customer-owned health insurer in the United States, operating Blue Cross and Blue Shield® Plans in Illinois, Montana, New Mexico, Oklahoma, and Texas Redwood City, CA, March 15, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive
